Implantation of Markers for the Radiotherapy of Lung Cancer Patients
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Richmond |
| State: |
|
Virginia |
| Zip Code: |
|
23298 |
| Conditions: |
|
Lung Cancer |
| Purpose: |
|
This clinical trial studies imaging markers in planning radiation therapy in patients with
lung cancer. Implanting markers in the tumor that can be seen using imaging procedures
during radiation therapy may allow x-rays to be sent directly to the tumor and cause less
damage to normal tissue.
|
| Study Summary: |
|
OBJECTIVES:
- To acquire experience in the marker implantation process for mediastinal lymph nodes
and primary lung tumors in patients with stage I-IIIB non-small cell lung cancer.
- To characterize the potential side effects involved in the use of markers in these
patients.
- To analyze the positional stability of lung markers in these patients over a
radiotherapy series.
- To acquire experience in the use of markers for treatment planning and radiotherapy in
these patients.
OUTLINE: Patients undergo implantation of ≥ 1 small radio-opaque Visicoil™ marker into or
close to the primary lesion and affected lymph nodes by bronchoscopy. Patients then undergo
x-rays to document marker location, detect potentially dropped markers, and diagnose
operation-related side effects (i.e., pneumothorax). After marker implantation, patients
undergo stereotactic or conventionally fractionated radiotherapy for 30-33 daily fractions.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Diagnosis of non-small cell lung cancer
- Stage I-IIIB disease
- No prior surgical tumor resection
- Respiration-induced tumor motion > 5 mm
- Recruited by attending physician or research nurse at the Medical College of Virginia
Hospitals
PATIENT CHARACTERISTICS:
- Not pregnant
- No insufficient lung function or other parameters prohibiting a bronchoscopy
- Not a prisoner or institutionalized
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Concurrent chemotherapy allowed
|
| NCT ID: |
|
NCT00856427 |
| Primary Contact: |
|
Principal Investigator
Elisabeth Weiss, MD
Massey Cancer Center
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Richmond, Virginia 23298
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|